fbpx
The Max Foundation Delivers First Treatment into Mozambique

The Max Foundation Delivers First Treatment into Mozambique

On November 1, 2019, the first shipment of treatment arrived at the hospital in Maputo, Mozambique. This is the first country Max Access Solutions, The Max Foundation’s patient-centered access model, has expanded into without a former access program in place.

“The Max Access Solutions provides hope in the form of innovative cancer treatment in neglected regions of the world,” says Pat Garcia-Gonzalez, CEO of The Max Foundation. “Today we reached a new frontier and I am deeply grateful to all who made it possible.”

In the beginning of 2018, Cathy Scheepers, The Max Foundation’s Region Head of Africa & Middle East visited the hospital in Maputo and learned of over 100 chronic myeloid leukemia (CML) patients who were unable to access treatment. The only way patients could access treatment was to travel to South Africa, a challenging day of travel. Mozambique is one of the poorest countries in the world, and for the majority of people living there, traveling to find treatment was simply not an option.

“Over 100 patients who have had a five-year life expectancy now have access to live normal lives.” says Cathy. “We’re changing not only the physician and patient perspectives, but also the broader community perspective that cancer is not always a death sentence. There is hope if you have access to treatment.”

Thank you to all who made access to treatment in Mozambique a reality: the passionate donors, physicians in Maputo, Humanitarian PACT partner Novartis, advisors, and The Max Foundation’s global team members. Everyone involved worked tirelessly to expand the scope of Max Access Solutions into the hands of those awaiting treatment, and now, patients have the chance to spend more days with their families, communities, and loved ones.

The Max Foundation (Max) is a global health nonprofit organization dedicated to accelerating health equity. For more than 25 years, Max has pioneered practical, scalable, high-quality solutions to bring lifesaving treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope. Learn more at www.themaxfoundation.org

Related Articles

  • The Max Foundation Partners with Leading Pharmaceutical Company to Advance Health Equity Through Expanded CML Treatment Access for Patients in 36 Low-Middle-Income Countries

    Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12, 2022 – The Max Foundation (Max), a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally,….

  • New study confirms an excellent survival rate of cancer patients in a medication donation program

    New study confirms an excellent survival rate of cancer patients in a medication donation program

    A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.

  • The Max Foundation Creates Subsidiary Organization, MaxAid, to Further Mission

    Now in its 20th year, The Max Foundation is undergoing exciting strategic changes aimed at strengthening organizational efforts to improve global access to cancer treatment, care and support. To that end, we announce the launch of MaxAid, a subsidiary organization set up by The Max Foundation to further its mission. MaxAid is a Washington nonprofit corporation with its own IRS determination letter of 501(c)(3) public charity status.